Format

Send to

Choose Destination
See comment in PubMed Commons below
Arthritis Res Ther. 2004;6(2):41-4. Epub 2004 Feb 5.

Measuring effectiveness of drugs in observational databanks: promises and perils.

Author information

  • 1Division of Immunology, Department of Medicine, Stanford University, Palo Alto, CA, USA. eswar_krishnan@hotmail.com

Abstract

Observational databanks have inherent strengths and shortcomings. As in randomized controlled trials, poor design of these databanks can either exaggerate or reduce estimates of drug effectiveness and can limit generalizability. This commentary highlights selected aspects of study design, data collection and statistical analysis that can help overcome many of these inadequacies. An international metaRegister and a formal mechanism for standardizing and sharing drug data could help improve the utility of databanks. Medical journals have a vital role in enforcing a quality checklist that improves reporting.

PMID:
15059263
PMCID:
PMC400435
DOI:
10.1186/ar1151
[PubMed - indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for BioMed Central Icon for PubMed Central
    Loading ...
    Support Center